Mammoth next step in Bayer's strengthening of cell and gene platform

10 January 2022
bayer_big

German pharma major Bayer (BAYN: DE) took another step towards its goal of becoming a leader in cell and gene therapies by announcing a strategic collaboration and option agreement with Mammoth Biosciences.

Privately-held Californian firm Mammoth, which has a vision to unlock the full potential of new CRISPR systems, is to receive an upfront sum of $40 million from Bayer, as well as potential future milestone payments of more than $1 billion.

"Will allow us to unleash the full potential of our cell and gene therapy strategy"Mammoth’s gene-editing capability is a key enabling technology, as well as a stand-alone therapeutic modality.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology